Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae

Sundeep Chaitanya Vedithi, Sony Malhotra, Madhusmita Das, Sheela Daniel, Nanda Kishore, Anuja George, Shantha Arumugam, Lakshmi Rajan, Mannam Ebenezer, David B. Ascher, Eddy Arnold, Tom L. BlundellScientific 2018 · DOI

TL;DR

This study investigates the structural basis of rifampin resistance in Mycobacterium leprae, the causative agent of leprosy. By modeling mutations in the rpoB gene, the researchers reveal how specific amino acid changes disrupt rifampin binding to RNA polymerase, leading to drug resistance and impacting treatment outcomes.

What Problem Does This Paper Address?

Leprosy, a chronic infectious disease, is primarily treated with multidrug therapy (MDT), which includes rifampin. However, the emergence of drug resistance, particularly to rifampin, poses a significant threat to global eradication efforts. While mutations in the rpoB gene are known to cause rifampin resistance, understanding the precise structural and functional consequences of these mutations in Mycobacterium leprae has been limited. Current methods for detecting drug resistance, such as mouse footpad propagation, are slow and challenging. This paper aims to bridge this gap by using computational modeling to elucidate how specific rpoB mutations identified in relapsed leprosy patients affect rifampin binding and RNA polymerase function, providing a molecular basis for resistance.

Methods

The researchers employed a multi-pronged approach combining molecular biology, computational modeling, and structural analysis.

  • DNA Extraction and Sequencing: DNA was extracted from skin biopsies of 35 leprosy patients who were relapsed or non-responsive to MDT. The rifampin resistance-determining region (RRDR) of the rpoB gene was amplified via PCR and subsequently sequenced to identify specific mutations.
  • Comparative Modeling: Three-dimensional comparative models of wild-type and mutant M. leprae RNA polymerase (RNAP) holoenzyme were constructed. These models were based on recently solved crystal structures of Mycobacterium tuberculosis RNAP, which shares high sequence identity with M. leprae RNAP. The models incorporated a synthetic nucleic acid scaffold and rifampin.
  • Structural and Functional Analysis: In-house computational tools and established software (mCSM, SDM, ENCOM, FoldX4) were used to analyze the impact of identified mutations on:
  • Protein stability and ligand interactions.
  • Protein-nucleic acid and protein-protein interactions.
  • Conformational flexibility of the RNAP complex.
  • Interatomic Interaction Analysis: Tools like Arpeggio and Intermezzo were used to analyze hydrogen bonding, hydrophobic, and other interatomic interactions between rifampin and the RNAP binding pocket, as well as within the RNAP complex itself.

Datasets

  • Patient Samples: DNA was extracted from skin biopsies of 35 relapsed or multidrug therapy non-respondent leprosy patients from three hospitals in southern India.
  • Structural Templates: Crystal structures of Mycobacterium tuberculosis RNAP (PDB IDs: 5UH5 and 5UHC) were used as templates for comparative modeling of M. leprae RNAP.

Key Insights and Ideas

  • Direct Link Between Mutations and Resistance: The study identified four specific mutations (D441Y, D441V, S437L, and H476R) in the rpoB gene of M. leprae from relapsed leprosy patients, directly linking these genetic alterations to rifampin resistance.
  • Disruption of Rifampin Binding: Mutations at positions D441 and S437 were found to directly impact the rifampin binding pocket. D441Y and D441V mutations introduce hydrophobic interactions and alter hydrogen bonding, while S437L introduces an aliphatic residue that disrupts the pocket's structure and interactions.
  • Allosteric Impact of H476R: The H476R mutation, though located further from the direct binding site, was predicted to destabilize the RNAP complex through altered inter-subunit interactions, potentially leading to an allosteric mechanism of resistance.
  • Conservation of Key Residues: The study highlights that the mutated residues (D441, S437, H476) are conserved across various mycobacterial species, suggesting a fundamental role in RNAP function and drug interaction.
  • Computational Power for Drug Resistance: The research demonstrates the utility of computational modeling in understanding drug resistance mechanisms, especially when experimental validation is challenging due to the obligate intracellular nature of M. leprae.

Key Results

  • Identification of Four Mutations: Four specific mutations (D441Y, D441V, S437L, and H476R) were identified in the rpoB gene of four out of 35 relapsed/non-respondent leprosy cases.
  • Structural Alterations:
    • D441Y and D441V mutations were predicted to enhance RNAP complex stability, potentially allowing transcription to continue in the presence of rifampin.
  • S437L mutation was predicted to destabilize both the protein and its interactions with rifampin, impacting transcription.
  • H476R mutation was predicted to destabilize the protein and its interactions with ligand and nucleic acids, potentially through an allosteric mechanism.
  • Destabilization of Rifampin-RNAP Interactions: Computational predictions consistently indicated that all identified mutations destabilize the interactions between rifampin and the RNAP complex.
  • Impact on Protein Dynamics: Normal mode analysis suggested that mutations can affect the conformational flexibility of RNAP, potentially influencing rifampin binding and resistance.

Limitations and Future Work

  • Experimental Validation: The study acknowledges the lack of experimental validation for the predicted structural and functional changes in rifampin-RNAP interactions due to the difficulty in culturing M. leprae.
  • Surrogate Models: The authors suggest that future work could involve using surrogate models like M. smegmatis or transplanting M. leprae residues into M. tuberculosis or M. smegmatis RNAPs for experimental validation through crystallography or cryo-electron microscopy.
  • Clinical Outcome Correlation: While the mutations were identified in relapsed patients, further experimental validation is needed to definitively link these structural changes to clinical outcomes and to differentiate between relapse due to persisters and reinfection.
  • Broader Implications: The study proposes that this computational approach can be extended to study novel mutations in drug targets to gain preliminary insights into their structural and functional impacts, aiding in the development of new therapeutic strategies.

Summary updated

Abstract

The rpoB gene encodes the β subunit of RNA polymerase holoenzyme in Mycobacterium leprae (M. leprae). Missense mutations in the rpoB gene were identified as etiological factors for rifampin resistance in leprosy. In the present study, we identified mutations corresponding to rifampin resistance in relapsed leprosy cases from three hospitals in southern India which treat leprosy patients. DNA was extracted from skin biopsies of 35 relapse/multidrug therapy non-respondent leprosy cases, and PCR was performed to amplify the 276 bp rifampin resistance-determining region of the rpoB gene. PCR products were sequenced, and mutations were identified in four out of the 35 cases at codon positions D441Y, D441V, S437L and H476R. The structural and functional effects of these mutations were assessed in the context of three-dimensional comparative models of wild-type and mutant M. leprae RNA polymerase holoenzyme (RNAP), based on the recently solved crystal structures of RNAP of Mycobacterium tuberculosis, containing a synthetic nucleic acid scaffold and rifampin. The resistance mutations were observed to alter the hydrogen-bonding and hydrophobic interactions of rifampin and the 5' ribonucleotide of the growing RNA transcript. This study demonstrates that rifampin-resistant strains of M. leprae among leprosy patients in southern India are likely to arise from mutations that affect the drug-binding site and stability of RNAP.
BibTeX
@inproceedings{vedithi2018structural,
  author = {Sundeep Chaitanya Vedithi and Sony Malhotra and Madhusmita Das and Sheela Daniel and Nanda Kishore and Anuja George and Shantha Arumugam and Lakshmi Rajan and Mannam Ebenezer and David B. Ascher and Eddy Arnold and Tom L. Blundell},
  title = {{Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae}},
  booktitle = {Scientific},
  year = {2018},
  doi = {10.1038/s41598-018-23423-1},
}
Figure